NEWS Oncoscience AG and GenIlac agree on cooperation terms in Turkey ByOncoscience 7. July 201017. July 2025
NEWS Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009 ByOncoscience 9. October 200917. July 2025
NEWS Funcrypta – Poster presentation at European Bioperspectives ByOncoscience 4. October 200817. July 2025
NEWS Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer. ByOncoscience 22. April 200817. July 2025
NEWS The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively ByOncoscience 26. October 200717. July 2025
NEWS Oncoscience AG reports marketing authorization approval for Theraloc® (Nimotuzumab) in the Ukraine ByOncoscience 13. October 200717. July 2025
NEWS Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancer ByOncoscience 12. September 200717. July 2025
NEWS Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy ByOncoscience 8. June 200717. July 2025
NEWS YM BioSciences partner Oncoscience AG reports update of pediatric brain cancer data ByOncoscience 30. September 200517. July 2025
